Abstracts tagged "Biologics"

Abstract Number: 1146 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany
Christian Gissel¹, Georg Götz², Holger Repp³ and Uwe Lange⁴, ¹Rheumatology, Justus-Liebig-University Giessen, Giessen, Germany, ²Department of Economics and Business, Justus-Liebig-University Giessen, Giessen, Germany, ³Department of Medicine, Justus-Liebig-University Giessen, Giessen, Germany, ⁴Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Clinic, Bad Nauheim, Germany
Background/Purpose: In Germany, Rheumatoid Arthritis (RA) can be treated with TNF-α inhibitors after the failure of conventional disease-modifying antirheumatic drugs like Methotrexate. The clinical use…
Abstract Number: 505 • 2014 ACR/ARHP Annual Meeting
A Structured Approach for Comparative Benefit-Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis
Ani John¹, George Quartey¹, Patricia B. Lehane², Nicole Mairon³, Michael Schulte³, Ashwini Shewade¹, Carol Chung¹ and Dominic Borie¹, ¹Genentech, Inc, South San Francisco, CA, ²Roche Products Ltd, Welwyn Garden City, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Rituximab in combination with methotrexate (MTX) is indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who have…
Abstract Number: 2519 • 2014 ACR/ARHP Annual Meeting
Are Patients with Rheumatoid Arthritis Initiating a TNF Biologic Comparable to Patients Initiating a Non TNF?
Kaleb Michaud^1,2, Kunal Gandhi³, Teresa Simon⁴ and Sofia Pedro¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb, Hopewell, NJ
Background/Purpose: Comparative research has gained attention in the field of Rheumatology. Evaluations of baseline characteristics in patients receiving similar treatments are critical in the…
Abstract Number: 1589 • 2014 ACR/ARHP Annual Meeting
Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis/Psoriatic arthritis (PsO/PsA) often requires treatment with systemic agents. Some of these agents are associated with infectious adverse events. Few studies have described the…
Abstract Number: 1145 • 2014 ACR/ARHP Annual Meeting
Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post-Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis
J. Harnett¹, D. Wiederkehr¹, R. Gerber², D. Gruben², A. Koenig³ and J. Bourret³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: For rheumatoid arthritis (RA) patients (pts) with inadequate response to a TNF inhibitor (TNFi), limited evidence exists from observational studies and indirect comparisons of…
Abstract Number: 495 • 2014 ACR/ARHP Annual Meeting
Discontinuation of Biologics in Patients with Rheumatoid Arthritis after Achieving Low-Activity Disease Status
Moeko Ochiai¹, Eri Sato¹, Eiichi Tanaka¹, Eisuke Inoue¹, Ayako Nakajima¹, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka², ¹Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Several clinical trials have reported bio-free remission or discontinuation of biologic DMARDs; however, these findings have not been confirmed in a real-world setting. The…
Abstract Number: 2503 • 2014 ACR/ARHP Annual Meeting
Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients
Paul Emery¹, Ronald Pedersen², Jack Bukowski³ and Lisa Marshall⁴, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, ²Specialty Care, Pfizer Inc, Collegeville, PA, ³Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose: In early rheumatoid arthritis (RA), achievement of clinical remission and low disease activity (LDA) limits joint damage and disability.1 Anti-TNF agents are effective in…
Abstract Number: 1601 • 2014 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis?
John Kelsall¹, William Bensen², Wojciech Olszynski³, Niall Jones⁴, Isabelle Fortin⁵, Andrew Chow⁶, Milton Baker⁷, Saeed Shaikh⁸, Denis Choquette⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, May Shawi¹¹, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁵Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁶McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ⁷University of Victoria, Victoria, BC, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The prevalence of ankylosing spondylitis (AS) is 2-3 times higher in men compared to women whereas psoriatic arthritis (PsA) is generally considered a disease…
Abstract Number: 1143 • 2014 ACR/ARHP Annual Meeting
Preferences of Biologic Treatment Characteristics Among Rheumatoid Arthritis Patients Who Are Current Biologic Therapy Users
David M. Kern¹, Angela E. Williams², Ozgur Tunceli¹, Bingcao Wu¹, Judy Stephenson¹, Laura Horne³ and Alfred Sackeyfio⁴, ¹HealthCore, Inc., Wilmington, DE, ²MedImmune, LLC, Cambridge, United Kingdom, ³AstraZeneca, Wilmington, DE, ⁴AstraZeneca, Manchester, United Kingdom
Background/Purpose: To identify the most and least important characteristics of rheumatoid arthritis (RA) treatment according to patients currently on biologic therapy. Methods: From the HealthCore…
Abstract Number: 493 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD
C. Charles-Schoeman¹, Gerd Burmester², P. Nash³, C.a.F. Zerbini⁴, S. Anway⁵, K. Kwok⁶, T. Hendrikx⁷, E. Bananis⁸ and Roy Fleischmann⁹, ¹University of California, Los Angeles, CA, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer BV, Capelle aan den IJssel, Netherlands, ⁸Pfizer Inc, Collegeville, PA, ⁹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the efficacy and safety of tofacitinib 5…
Abstract Number: 2497 • 2014 ACR/ARHP Annual Meeting
Correlation Between Time to Switch and Clinical Response Amplitude to Rituximab in Second Line Treatment in Rheumatoid Arthritis Patients with Treatment Failure to Tumor Necrosis Factor Inhibitors: 3-Year Data from Repeat Observational Study
Ioan Ancuta¹, Ruxandra Ionescu², Catalin Codreanu³, Andra Balanescu², Elena Rezus⁴, Maria Suta⁵, Paulina Ciurea⁶, Mihaela Milicescu⁷, Dan Nemes⁸, Codrina Ancuta⁹, Mihai Bojinca¹⁰, Magda Parvu¹¹ and Horatiu Popoviciu¹², ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³5 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ⁴Rheumatology, Recovering Clinical Hospital, Iasi, Romania, ⁵317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, ⁶Clinical County Hospital,Craiova, Craiova, Romania, ⁷Rheumatology, "Dr. I. Cantacuzino" Clinical Hospital, Bucharest, Romania, ⁸Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁹G.T.Popa Center for Biomedical Research, Iasi, Romania, ¹⁰Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ¹¹Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, ¹²Rheumatology, University of Medicine and Pharmacy Targu Mures, Tg Mures, Romania
Background/Purpose: In recent years we assist to an increasing interest to get more clinical data to improve the control of disease course in rheumatoid arthritis…
Abstract Number: 1569 • 2014 ACR/ARHP Annual Meeting
Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry
Alan Menter¹, Kim Papp², Gerald G. Krueger³, Matthias Augustin⁴, Francisco Kerdel⁵, Melinda Gooderham⁶, Kavitha Goyal⁷, Steve Fakharzadeh⁸, Wayne Langholff⁹, Jan Sermon¹⁰, Steve Calabro⁷ and David Pariser¹¹, ¹Baylor Research Institute, Dallas, TX, ²Probity Medical Research, Waterloo, ON, Canada, ³Dermatology, University of Utah, Salt Lake City, UT, ⁴University Clinics of Hamburg, Hamburg, Germany, ⁵University of Miami, Miami, FL, ⁶SKiN Centre for Dermatology, Peterborough, ON, Canada, ⁷Janssen Services, LLC, Horsham, PA, ⁸Janssen Services, LLC, Spring House, PA, ⁹Janssen Research and Development, LLC, Spring House, PA, ¹⁰Janssen-Cilag, Beerse, Belgium, ¹¹Eastern Virginia Medical School and Virginia Clinical Research, Inc, Norfolk, VA
Background/Purpose We evaluated persistency (treatment longevity) of biologics in patients (pts) with psoriasis (PsO), as well as with psoriatic arthritis (PsA) in the context of…
Abstract Number: 1142 • 2014 ACR/ARHP Annual Meeting
Healthcare Costs Associated with Serious Infections Among Biologic-Naïve Rheumatoid Arthritis Patients Initiating First-Line Biologic Treatment
S Johnston¹, S Kelly², A Nadkarni², K Wilson¹, B Limone¹ and M Hochberg³, ¹Truven Health Analytics, Bethesda, MD, ²Bristol-Myers Squibb, Plainsboro, NJ, ³Medicine, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The risk of serious infections can vary across biologics. For example, in the 2-year AMPLE trial, serious infections occurred in 3.8% of SC abatacept-treated…
Abstract Number: 125 • 2014 ACR/ARHP Annual Meeting
PD Signal Detected By Ultrasonography Relates to Joint Destruction in Rheumatoid Arthritis Under Biologics Therapy in Real World
Maasa Hama¹, Yumiko Sugiyama¹, Naomi Tsuchida¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Reikou Kamiyama¹, Kaoru Minegishi-Takase¹, Ryusuke Yoshimi¹, Yohei Kirino², Mitsuhiro Takeno³, Atsuhisa Ueda¹ and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
Background/Purpose: Biologic DMARD (biologics) therapy for rheumatoid arthritis (RA) strongly suppresses joint destruction regardless of its efficacy for disease activity. On the contrary power Doppler…
Abstract Number: 2491 • 2014 ACR/ARHP Annual Meeting
Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study
H Nüßlein¹, R Alten², M Galeazzi³, HM Lorenz⁴, MT Nurmohamed⁵, WG Bensen⁶, Gerd Burmester⁷, H-H Peter⁸, P Peichl⁹, K Pavelka¹⁰, M Chartier¹¹, C Poncet¹², C Rauch¹³ and M Le Bars¹⁴, ¹Internistische Schwerpunktpraxis, Nürnberg, Germany, ²Schlosspark-Klinik University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵VU Univ Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Charité-Universitätsmedizin, Berlin, Germany, ⁸University of Freiburg, Freiburg, Germany, ⁹Evangelisches Krankenhaus, Vienna, Austria, ¹⁰Institute of Rheumatology, Prague, Czech Republic, ¹¹Chiltern International, Neuilly, France, ¹²Docs International, Nanterre, France, ¹³Bristol-Myers Squibb, Munich, Germany, ¹⁴Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: To identify prognostic factors of retention for abatacept (ABA) treatment in patients (pts) with moderate-to-severe RA, using final results from the real-world ACTION study.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].